{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:06:41Z","timestamp":1780045601824,"version":"3.53.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K21 GM000680"],"award-info":[{"award-number":["K21 GM000680"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K05 DA031246"],"award-info":[{"award-number":["K05 DA031246"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51OD11132"],"award-info":[{"award-number":["P51OD11132"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00213-017-4812-5","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T21:26:00Z","timestamp":1513459560000},"page":"377-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["(\u00b1)-MDMA and its enantiomers: potential therapeutic advantages of R(\u2212)-MDMA"],"prefix":"10.1007","volume":"235","author":[{"given":"Elizabeth G.","family":"Pitts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly N.","family":"Hampshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard L.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,16]]},"reference":[{"issue":"1","key":"4812_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1471-4159.2007.04451.x","volume":"102","author":"E Acquas","year":"2007","unstructured":"Acquas E, Pisanu A, Spiga S, Plumitallo A, Zernig G, Di Chiara G (2007) Differential effects of intravenous R,S-(+\/\u2212)-3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its S(+)- and R(\u2212)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell. J Neurochem 102(1):121\u2013132. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04451.x","journal-title":"J Neurochem"},{"key":"4812_CR2","first-page":"59","volume":"10","author":"S Adamson","year":"1988","unstructured":"Adamson S, Metzner R (1988) The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice. ReVision 10:59\u201372","journal-title":"ReVision"},{"issue":"5","key":"4812_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2015.1094156","volume":"00","author":"T Amoroso","year":"2015","unstructured":"Amoroso T (2015) The psychopharmacology of \u00b13,4 methylenedioxymethamphetamine and its role in the treatment of posttraumatic stress disorder. J Psychoactive Drugs 00(5):1\u20138. https:\/\/doi.org\/10.1080\/02791072.2015.1094156","journal-title":"J Psychoactive Drugs"},{"issue":"7","key":"4812_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1177\/0269881116642542","volume":"30","author":"T Amoroso","year":"2016","unstructured":"Amoroso T, Workman M (2016) Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. J Psychopharmacol (Oxf, Engl) 30(7):595\u2013600. https:\/\/doi.org\/10.1177\/0269881116642542","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"key":"4812_CR5","unstructured":"Anderson GM, Braun G, Braun U, Nichols DE, Shulgin aT (1978) Absolute configuration and psychotomimetic activity. NIDA Res Monogr: 8\u201315"},{"issue":"7","key":"4812_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.neuropharm.2005.12.010","volume":"50","author":"RD Ando","year":"2006","unstructured":"Ando RD, Benko A, Ferrington L, Kirilly E, Kelly PA, Bagdy G (2006) Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test. Neuropharmacology 50(7):884\u2013896. https:\/\/doi.org\/10.1016\/j.neuropharm.2005.12.010","journal-title":"Neuropharmacology"},{"issue":"2","key":"4812_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0147136","volume":"11","author":"S Ballesta","year":"2016","unstructured":"Ballesta S, Reymond G, Pozzobon M, Duhamel JR (2016) Effects of MDMA injections on the behavior of socially-housed long-tailed macaques (Macaca fascicularis). PLoS One 11(2):1\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0147136","journal-title":"PLoS One"},{"issue":"1-2","key":"4812_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","volume":"149","author":"G Battaglia","year":"1988","unstructured":"Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149(1-2):159\u2013163. https:\/\/doi.org\/10.1016\/0014-2999(88)90056-8","journal-title":"Eur J Pharmacol"},{"key":"4812_CR9","unstructured":"BBC (2001) Ecstasy & Agony"},{"issue":"1","key":"4812_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/157015911795017146","volume":"9","author":"DK Biezonski","year":"2011","unstructured":"Biezonski DK, Meyer JS (2011) The nature of 3, 4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: evidence for and against the neurodegeneration hypothesis. Curr Neuropharmacol 9(1):84\u201390. https:\/\/doi.org\/10.2174\/157015911795017146","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"4812_CR11","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/adb.12069","volume":"19","author":"S Bradbury","year":"2014","unstructured":"Bradbury S, Bird J, Colussi-Mas J, Mueller M, Ricaurte G, Schenk S (2014) Acquisition of MDMA self-administration: pharmacokinetic factors and MDMA-induced serotonin release. Addict Biol 19(5):874\u2013884. https:\/\/doi.org\/10.1111\/adb.12069","journal-title":"Addict Biol"},{"issue":"14","key":"4812_CR12","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","volume":"283","author":"K Brady","year":"2000","unstructured":"Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM (2000) Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 283(14):1837\u20131844. https:\/\/doi.org\/10.1001\/jama.283.14.1837","journal-title":"JAMA"},{"issue":"1","key":"4812_CR13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0022-3565(25)12053-3","volume":"275","author":"HW Broening","year":"1995","unstructured":"Broening HW, Bowyer JF, Slikker W (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+\/\u2212)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275(1):325\u2013333","journal-title":"J Pharmacol Exp Ther"},{"issue":"3-4","key":"4812_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000253550","volume":"60","author":"R Bruno","year":"2009","unstructured":"Bruno R, Matthews AJ, Topp L, Degenhardt L, Gomez R, Dunn M (2009) Can the severity of dependence scale be usefully applied to \u2018ecstasy\u2019? Neuropsychobiology 60(3-4):137\u2013147. https:\/\/doi.org\/10.1159\/000253550","journal-title":"Neuropsychobiology"},{"issue":"01","key":"4812_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4088\/PCC.v04n0107","volume":"4","author":"WJ Burke","year":"2002","unstructured":"Burke WJ, Kratochvil CJ (2002) Stereoisomers in psychiatry: the case of escitalopram. Prim Care Compan J Clin Psychiatry 4(01):20\u201324. https:\/\/doi.org\/10.4088\/PCC.v04n0107","journal-title":"Prim Care Compan J Clin Psychiatry"},{"issue":"4","key":"4812_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","volume":"20","author":"J Cami","year":"2000","unstructured":"Cami J, Farr\u00e9 M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): psychomotor performance and subjective effects. J Clin Psychopharmacol 20(4):455\u2013466. https:\/\/doi.org\/10.1097\/00004714-200008000-00010","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4812_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12035-009-8064-1","volume":"39","author":"JP Capela","year":"2009","unstructured":"Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F (2009) Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39(3):210\u2013271. https:\/\/doi.org\/10.1007\/s12035-009-8064-1","journal-title":"Mol Neurobiol"},{"issue":"3","key":"4812_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0300-9629(97)00132-1","volume":"118","author":"A Capurro","year":"1997","unstructured":"Capurro A, Reyes-Parada M, Olazabal D, Perrone R, Silveira R, Macadar O (1997) Aggressive behavior and jamming avoidance response in the weakly electric fish Gymnotus carapo: effects of 3,4-methylenedioxymethamphetamine (MDMA). Comp Biochem Physiol - A Physiology 118(3):831\u2013840. https:\/\/doi.org\/10.1016\/S0300-9629(97)00132-1","journal-title":"Comp Biochem Physiol - A Physiology"},{"key":"4812_CR19","unstructured":"Center for Behavioral Health Statistics and Quality (2015) Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15\u20134927, NSDUH Series H-50). Retrieved from http:\/\/www.samhsa.gov\/data\/"},{"issue":"1","key":"4812_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0925-4927(99)00048-7","volume":"98","author":"L Chang","year":"2000","unstructured":"Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 98(1):15\u201328. https:\/\/doi.org\/10.1016\/S0925-4927(99)00048-7","journal-title":"Psychiatry Res"},{"key":"4812_CR21","doi-asserted-by":"publisher","unstructured":"Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, Lee LC, Pettygrove S, Robinson C, Schulz E, Wells C, Wingate MS, Zahorodny W, Yeargin-Allsopp M (2016) Prevalence and characteristics of autism spectrum disorder among children aged 8 years\u2014autism and developmental disabilities monitoring network, 11 sites, United States, 2012. Morbidity and mortality weekly report surveillance summaries (Washington, DC: 2002) 65:1\u201323. Doi: https:\/\/doi.org\/10.15585\/mmwr.ss6503a1","DOI":"10.15585\/mmwr.ss6503a1"},{"issue":"4","key":"4812_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.bjp.0702373","volume":"126","author":"MI Colado","year":"1999","unstructured":"Colado MI, O'Shea E, Granados R, Esteban B, Mart\u00edn AB, Green AR (1999) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of dark agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or \u2018ecstasy\u2019) administration. Br J Pharmacol 126(4):911\u2013924. https:\/\/doi.org\/10.1038\/sj.bjp.0702373","journal-title":"Br J Pharmacol"},{"key":"4812_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neuropharm.2017.10.003","volume":"128","author":"DW Curry","year":"2017","unstructured":"Curry DW, Young MB, Tran AN, Daoud GE, Howell LL (2017) Separating the agony from ecstasy: R(\u2212)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Neuropharmacology 128:196\u2013206","journal-title":"Neuropharmacology"},{"key":"4812_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pnpbp.2015.03.011","volume":"64","author":"AL Danforth","year":"2016","unstructured":"Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS (2016) MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults. Prog Neuro-Psychopharmacol Biol Psychiatry 64:237\u2013249. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.03.011","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"4812_CR25","first-page":"242","volume":"1","author":"NM Davies","year":"2003","unstructured":"Davies NM, Teng XW (2003) Importance of chirality in drug therapy and pharmacy practice: implications for psychiatry. Adv Pharm 1:242\u2013252","journal-title":"Adv Pharm"},{"issue":"1","key":"4812_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ntt.2008.07.005","volume":"31","author":"M Daza-Losada","year":"2009","unstructured":"Daza-Losada M, Rodriguez-Arias M, Maldonado C, Aguilar MA, Guerri C, Minarro J (2009) Acute behavioural and neurotoxic effects of MDMA plus cocaine in adolescent mice. Neurotoxicol Teratol 31(1):49\u201359. https:\/\/doi.org\/10.1016\/j.ntt.2008.07.005","journal-title":"Neurotoxicol Teratol"},{"issue":"2","key":"4812_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/02791072.2002.10399952","volume":"34","author":"R Doblin","year":"2002","unstructured":"Doblin R (2002) A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoactive Drugs 34(2):185\u2013194. https:\/\/doi.org\/10.1080\/02791072.2002.10399952","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"4812_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/hup.2389","volume":"29","author":"R Doblin","year":"2014","unstructured":"Doblin R, Greer G, Holland J, Jerome L, Mithoefer MC, Sessa B (2014) A reconsideration and response to Parrott AC (2013) \u201chuman psychobiology of MDMA or \u2018ecstasy\u2019: an overview of 25 years of empirical research\u201d. Hum Psychopharmacol 29(2):105\u2013108. https:\/\/doi.org\/10.1002\/hup.2389","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"4812_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/02791072.1986.10472366","volume":"18","author":"J Downing","year":"1986","unstructured":"Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18(4):335\u2013340. https:\/\/doi.org\/10.1080\/02791072.1986.10472366","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"4812_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17470910802649470","volume":"4","author":"GJ Dumont","year":"2009","unstructured":"Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, van Gerven JM, Buitelaar JK, Verkes RJ (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 4(4):359\u2013366. https:\/\/doi.org\/10.1080\/17470910802649470","journal-title":"Soc Neurosci"},{"issue":"5","key":"4812_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.npp.1300412","volume":"29","author":"AB Emiliano","year":"2004","unstructured":"Emiliano AB, Fudge JL (2004) From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29(5):833\u2013846. https:\/\/doi.org\/10.1038\/sj.npp.1300412","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"4812_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/archgenpsychiatry.2011.56","volume":"68","author":"D Erritzoe","year":"2011","unstructured":"Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, Madsen J, Rasmussen PM, Ramsoy T, Jernigan TL, Knudsen GM (2011) In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or \u201cecstasy\u201d) and hallucinogen users. Arch Gen Psychiatry 68(6):562\u2013576. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.56","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"4812_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0091-3057(02)00728-1","volume":"72","author":"EM Falk","year":"2002","unstructured":"Falk EM, Cook VJ, Nichols DE, Sprague JE (2002) An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav 72(3):617\u2013622. https:\/\/doi.org\/10.1016\/S0091-3057(02)00728-1","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"4812_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/1064-1297.16.1.1","volume":"16","author":"WE Fantegrossi","year":"2008","unstructured":"Fantegrossi WE (2008) In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys. Exp Clin Psychopharmacol 16(1):1\u201312. https:\/\/doi.org\/10.1037\/1064-1297.16.1.1","journal-title":"Exp Clin Psychopharmacol"},{"issue":"4","key":"4812_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00213-002-1021-6","volume":"161","author":"WE Fantegrossi","year":"2002","unstructured":"Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002) 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161(4):356\u2013364. https:\/\/doi.org\/10.1007\/s00213-002-1021-6","journal-title":"Psychopharmacology"},{"issue":"3","key":"4812_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00213-002-1261-5","volume":"166","author":"WE Fantegrossi","year":"2003","unstructured":"Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH (2003) Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166(3):202\u2013211. https:\/\/doi.org\/10.1007\/s00213-002-1261-5","journal-title":"Psychopharmacology"},{"issue":"1","key":"4812_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0006-8993(92)91460-V","volume":"595","author":"GM Farfel","year":"1992","unstructured":"Farfel GM, Vosmer GL, Seiden LS (1992) The N-methyl-d-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Brain Res 595(1):121\u2013127. https:\/\/doi.org\/10.1016\/0006-8993(92)91460-V","journal-title":"Brain Res"},{"issue":"10","key":"4812_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1211\/0022357011777855","volume":"53","author":"M Forsling","year":"2001","unstructured":"Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): is metabolism a contributory factor? J Pharm Pharmacol 53(10):1357\u20131363. https:\/\/doi.org\/10.1211\/0022357011777855","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"4812_CR39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjp.0704502","volume":"135","author":"ML Forsling","year":"2002","unstructured":"Forsling ML, Fallon JK, Shah D, Tilbrook GS, Da C, Kicman AT, Hutt AJ (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135(3):649\u2013656. https:\/\/doi.org\/10.1038\/sj.bjp.0704502","journal-title":"Br J Pharmacol"},{"issue":"1","key":"4812_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/jnc.12060","volume":"124","author":"L Frau","year":"2013","unstructured":"Frau L, Simola N, Plumitallo A, Morelli M (2013) Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. J Neurochem 124(1):69\u201378. https:\/\/doi.org\/10.1111\/jnc.12060","journal-title":"J Neurochem"},{"issue":"3","key":"4812_CR41","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1046\/j.1471-4159.1995.65031250.x","volume":"65","author":"MY Globus","year":"1995","unstructured":"Globus MY, Busto R, Lin B, Schnippering H, Ginsberg MD (1995) Detection of free radical activity during transient global ischemia and recirculation: effects of intraischemic brain temperature modulation. J Neurochem 65(3):1250\u20131256","journal-title":"J Neurochem"},{"issue":"1","key":"4812_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s002130050860","volume":"142","author":"E Gouzoulis-Mayfrank","year":"1999","unstructured":"Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar K-A, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers. Psychopharmacology 142(1):41\u201350. https:\/\/doi.org\/10.1007\/s002130050860","journal-title":"Psychopharmacology"},{"issue":"3","key":"4812_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/pr.55.3.3","volume":"55","author":"AR Green","year":"2003","unstructured":"Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d). Pharmacol Rev 55(3):463\u2013508. https:\/\/doi.org\/10.1124\/pr.55.3.3","journal-title":"Pharmacol Rev"},{"issue":"4","key":"4812_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","volume":"18","author":"G Greer","year":"1986","unstructured":"Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18(4):319\u2013327. https:\/\/doi.org\/10.1080\/02791072.1986.10472364","journal-title":"J Psychoactive Drugs"},{"key":"4812_CR45","doi-asserted-by":"publisher","unstructured":"Greer G, Tolbert R (1990) The therapeutic use of MDMA. Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA SE - 2 9: 21-35. https:\/\/doi.org\/10.1007\/978-1-4613-1485-1_2","DOI":"10.1007\/978-1-4613-1485-1_2"},{"issue":"3","key":"4812_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1176\/appi.psychotherapy.1986.40.3.393","volume":"40","author":"L Grinspoon","year":"1986","unstructured":"Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40(3):393\u2013404","journal-title":"Am J Psychother"},{"issue":"1-2","key":"4812_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0166-4328(96)00078-2","volume":"73","author":"CS Grob","year":"1996","unstructured":"Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73(1-2):103\u2013107","journal-title":"Behav Brain Res"},{"issue":"1","key":"4812_CR48","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1002\/syn.10055","volume":"19","author":"G Hatzidimitriou","year":"1999","unstructured":"Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+\/\u2212)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci: Off J Soc Neurosci 19(1):5096\u20135107. https:\/\/doi.org\/10.1002\/syn.10055","journal-title":"J Neurosci: Off J Soc Neurosci"},{"issue":"8816","key":"4812_CR49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/0140-6736(92)91469-O","volume":"340","author":"JA Henry","year":"1992","unstructured":"Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d). Lancet 340(8816):384\u2013387. https:\/\/doi.org\/10.1016\/0140-6736(92)91469-O","journal-title":"Lancet"},{"issue":"3","key":"4812_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0028-3908(90)90012-G","volume":"29","author":"M Hiramatsu","year":"1990","unstructured":"Hiramatsu M, Cho AK (1990) Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29(3):269\u2013275. https:\/\/doi.org\/10.1016\/0028-3908(90)90012-G","journal-title":"Neuropharmacology"},{"key":"4812_CR51","unstructured":"Holland J (2001) Ecstasy: the complete guide 454"},{"issue":"19","key":"4812_CR52","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","volume":"31","author":"P Huot","year":"2011","unstructured":"Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2011) Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J Neurosci: Off J Soc Neurosci 31(19):7190\u20137198. https:\/\/doi.org\/10.1523\/JNEUROSCI.1171-11.2011","journal-title":"J Neurosci: Off J Soc Neurosci"},{"issue":"3","key":"4812_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00431629","volume":"51","author":"J Hyttel","year":"1977","unstructured":"Hyttel J (1977) Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology 51(3):225\u2013233. https:\/\/doi.org\/10.1007\/BF00431629","journal-title":"Psychopharmacology"},{"issue":"3","key":"4812_CR54","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0278-5846(82)80179-6","volume":"6","author":"J Hyttel","year":"1982","unstructured":"Hyttel J (1982) Citalopram\u2014pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol Biol Psychiatry 6(3):277\u2013295. https:\/\/doi.org\/10.1016\/S0278-5846(82)80179-6","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"8","key":"4812_CR55","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1176\/appi.ajp.158.8.1184","volume":"158","author":"LK Jacobsen","year":"2001","unstructured":"Jacobsen LK, Southwick SM, Kosten TR (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158(8):1184\u20131190. https:\/\/doi.org\/10.1176\/appi.ajp.158.8.1184","journal-title":"Am J Psychiatry"},{"issue":"1","key":"4812_CR56","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/18744737112059990005","volume":"6","author":"L Jerome","year":"2013","unstructured":"Jerome L, Schuster S, Yazar-Klosinski BB (2013) Can MDMA play a role in the treatment of substance abuse? Curr Drug Abuse Rev 6(1):54\u201362. https:\/\/doi.org\/10.2174\/18744737112059990005","journal-title":"Curr Drug Abuse Rev"},{"issue":"4","key":"4812_CR57","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0269881109102787","volume":"23","author":"PO Johansen","year":"2009","unstructured":"Johansen PO, Krebs TS (2009) How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol (Oxf, Engl) 23(4):389\u2013391. https:\/\/doi.org\/10.1177\/0269881109102787","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"issue":"2-3","key":"4812_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0014-2999(86)90615-1","volume":"132","author":"MP Johnson","year":"1986","unstructured":"Johnson MP, Hoffman AJ, Nichols DE (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132(2-3):269\u2013276. https:\/\/doi.org\/10.1016\/0014-2999(86)90615-1","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4812_CR59","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-3565(25)24573-6","volume":"244","author":"M Johnson","year":"1988","unstructured":"Johnson M, Letter AA, Merchant K, Hanson GR, Gibb JW (1988) Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J Pharmacol Exp Ther 244(3):977\u2013982","journal-title":"J Pharmacol Exp Ther"},{"key":"4812_CR60","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neubiorev.2015.08.016","volume":"57","author":"P Kamilar-Britt","year":"2015","unstructured":"Kamilar-Britt P, Bedi G (2015) The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci Biobehav Rev 57:433\u2013446. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.08.016","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"4812_CR61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/15299730802624577","volume":"10","author":"JL Kibler","year":"2009","unstructured":"Kibler JL (2009) Posttraumatic stress and cardiovascular disease risk. J Trauma Dissociation: Off J Int Soc Stud Dissociation (ISSD) 10(2):135\u2013150. https:\/\/doi.org\/10.1080\/15299730802624577","journal-title":"J Trauma Dissociation: Off J Int Soc Stud Dissociation (ISSD)"},{"key":"4812_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3200\/bmed.34.4.125-132","volume":"34","author":"JL Kibler","year":"2009","unstructured":"Kibler JL, Joshi K, Ma M (2009) Hypertension in relation to posttraumatic stress disorder and depression in the US National Comorbidity Survey. Behav Med (Washington, DC) 34:125\u2013132. https:\/\/doi.org\/10.3200\/bmed.34.4.125-132","journal-title":"Behav Med (Washington, DC)"},{"issue":"1","key":"4812_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00004647-199601000-00012","volume":"16","author":"HY Kil","year":"1996","unstructured":"Kil HY, Zhang J, Piantadosi CA (1996) Brain temperature alters hydroxyl radical production during cerebral ischemia\/reperfusion in rats. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab 16(1):100\u2013106. https:\/\/doi.org\/10.1097\/00004647-199601000-00012","journal-title":"J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab"},{"issue":"1","key":"4812_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00213-011-2383-4","volume":"219","author":"MG Kirkpatrick","year":"2012","unstructured":"Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL (2012) A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 219(1):109\u2013122. https:\/\/doi.org\/10.1007\/s00213-011-2383-4","journal-title":"Psychopharmacology"},{"issue":"2","key":"4812_CR65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0269881108097724","volume":"24","author":"SJ Kish","year":"2010","unstructured":"Kish SJ, Fitzmaurice PS, Chang LJ, Furukawa Y, Tong J (2010) Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study. J Psychopharmacol (Oxf, Engl) 24(2):281\u2013284. https:\/\/doi.org\/10.1177\/0269881108097724","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"issue":"4","key":"4812_CR66","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/JCP.0b013e31817ef470","volume":"28","author":"EA Kolbrich","year":"2008","unstructured":"Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Ma H (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28(4):432\u2013440. https:\/\/doi.org\/10.1097\/JCP.0b013e31817ef470","journal-title":"J Clin Psychopharmacol"},{"key":"4812_CR67","doi-asserted-by":"crossref","unstructured":"Kupferschmidt K (2017) All clear for the decisive trial of ecstasy in PTSD patients. Science Magazine","DOI":"10.1126\/science.aap7739"},{"issue":"6","key":"4812_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100719","volume":"9","author":"KP Kuypers","year":"2014","unstructured":"Kuypers KP, de la Torre R, Farre M, Yubero-Lahoz S, Dziobek I, Van den Bos W, Ramaekers JG (2014) No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One 9(6):e100719. https:\/\/doi.org\/10.1371\/journal.pone.0100719","journal-title":"PLoS One"},{"issue":"21","key":"4812_CR69","doi-asserted-by":"publisher","first-page":"8232","DOI":"10.1523\/jneurosci.1022-15.2015","volume":"35","author":"X Li","year":"2015","unstructured":"Li X, Rubio FJ, Zeric T, Bossert JM, Kambhampati S, Cates HM, Kennedy PJ, Liu QR, Cimbro R, Hope BT, Nestler EJ, Shaham Y (2015) Incubation of methamphetamine craving is associated with selective increases in expression of Bdnf and trkb, glutamate receptors, and epigenetic enzymes in cue-activated fos-expressing dorsal striatal neurons. J Neurosci: Off J Soc Neurosci 35(21):8232\u20138244. https:\/\/doi.org\/10.1523\/jneurosci.1022-15.2015","journal-title":"J Neurosci: Off J Soc Neurosci"},{"issue":"8","key":"4812_CR70","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Vollenweider FX (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum psychopharmacol 16(8):589\u2013598. https:\/\/doi.org\/10.1002\/hup.348","journal-title":"Hum psychopharmacol"},{"issue":"5","key":"4812_CR71","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s0893-133x(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22(5):513\u2013521. https:\/\/doi.org\/10.1016\/s0893-133x(99)00148-7","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"4812_CR72","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","volume":"23","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000b) Psychological and physiological effects of MDMA (\u2018ecstasy\u2019) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23(4):396\u2013404. https:\/\/doi.org\/10.1016\/S0893-133X(00)00126-3","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"4812_CR73","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00005053-199206000-00001","volume":"180","author":"MB Liester","year":"1992","unstructured":"Liester MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 180(6):345\u2013352; discussion 353-4. https:\/\/doi.org\/10.1097\/00005053-199206000-00001","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"4812_CR74","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF00178519","volume":"88","author":"RA Lyon","year":"1986","unstructured":"Lyon RA, Glennon RA, Titeler M (1986) 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88(4):525\u2013526","journal-title":"Psychopharmacology"},{"issue":"2","key":"4812_CR75","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.pbb.2012.04.013","volume":"102","author":"A Machalova","year":"2012","unstructured":"Machalova A, Slais K, Vrskova D, Sulcova A (2012) Differential effects of modafinil, methamphetamine, and MDMA on agonistic behavior in male mice. Pharmacol Biochem Behav 102(2):215\u2013223. https:\/\/doi.org\/10.1016\/j.pbb.2012.04.013","journal-title":"Pharmacol Biochem Behav"},{"issue":"13","key":"4812_CR76","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1523\/JNEUROSCI.18-13-05086.1998","volume":"18","author":"JE Malberg","year":"1998","unstructured":"Malberg JE, Seiden LS (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci: Off J Soc Neurosci 18(13):5086\u20135094","journal-title":"J Neurosci: Off J Soc Neurosci"},{"issue":"1","key":"4812_CR77","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0022-3565(25)20131-8","volume":"278","author":"JE Malberg","year":"1996","unstructured":"Malberg JE, Sabol KE, Seiden LS (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278(1):258\u2013267","journal-title":"J Pharmacol Exp Ther"},{"key":"4812_CR78","unstructured":"MAPS (2015) Clinical research with psychedelics"},{"issue":"2","key":"4812_CR79","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/npp.1994.15","volume":"10","author":"UD McCann","year":"1994","unstructured":"McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after (+\/\u2212)3,4-methylenedioxymethamphetamine (MDMA; \u201cecstasy\u201d): a controlled study in humans. Neuropsychopharmacology 10(2):129\u2013138. https:\/\/doi.org\/10.1038\/npp.1994.15","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"4812_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s002130051142","volume":"147","author":"UD McCann","year":"1999","unstructured":"McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA (1999) Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 147(1):56\u201365. https:\/\/doi.org\/10.1007\/s002130051142","journal-title":"Psychopharmacology"},{"key":"4812_CR81","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/sj.npp.1300736","volume":"30","author":"UD McCann","year":"2005","unstructured":"McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30:1741\u20131750","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"4812_CR82","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00213-008-1218-4","volume":"200","author":"UD McCann","year":"2008","unstructured":"McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2008) Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent 3,4-methylenedioxymethamphetamine (ecstasy) users: relationship to cognitive performance. Psychopharmacology 200(3):439\u2013450. https:\/\/doi.org\/10.1007\/s00213-008-1218-4","journal-title":"Psychopharmacology"},{"issue":"1","key":"4812_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00213-010-1818-7","volume":"210","author":"J McClung","year":"2010","unstructured":"McClung J, Fantegrossi W, Howell LL (2010) Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. Psychopharmacology 210(1):75\u201383. https:\/\/doi.org\/10.1007\/s00213-010-1818-7","journal-title":"Psychopharmacology"},{"key":"4812_CR84","unstructured":"McRae AL (2002) Escitalopram H Lundbeck. Current opinion in investigational drugs (London, England: 2000) 3:1225\u20139"},{"issue":"3","key":"4812_CR85","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0304-3940(02)00821-2","volume":"330","author":"A Meyer","year":"2002","unstructured":"Meyer A, Mayerhofer A, Kovar KA, Schmidt WJ (2002) Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine (\u2018Ecstasy\u2019) and 3,4-methylenedioxy-ethylamphetamine (\u2018Eve\u2019) measured by conditioned place preference in rats. Neurosci Lett 330(3):280\u2013284. https:\/\/doi.org\/10.1016\/S0304-3940(02)00821-2","journal-title":"Neurosci Lett"},{"issue":"11","key":"4812_CR86","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1124\/dmd.108.021543","volume":"36","author":"MR Meyer","year":"2008","unstructured":"Meyer MR, Peters FT, Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos: Biol Fate Chem 36(11):2345\u20132354. https:\/\/doi.org\/10.1124\/dmd.108.021543","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"4","key":"4812_CR87","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of {+\/\u2212}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (Oxf, Engl) 25(4):439\u2013452. https:\/\/doi.org\/10.1177\/0269881110378371","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"issue":"1","key":"4812_CR88","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0269881112456611","volume":"27","author":"MC Mithoefer","year":"2013","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol (Oxf, Engl) 27(1):28\u201339. https:\/\/doi.org\/10.1177\/0269881112456611","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"issue":"5","key":"4812_CR89","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","volume":"3","author":"MC Mithoefer","year":"2016","unstructured":"Mithoefer MC, Grob CS, Brewerton TD (2016) Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 3(5):481\u2013488. https:\/\/doi.org\/10.1016\/S2215-0366(15)00576-3","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"4812_CR90","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1034\/j.1600-0773.2001.d01-118.x","volume":"88","author":"SA Montgomery","year":"2001","unstructured":"Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M (2001) Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88(5):282\u2013286. https:\/\/doi.org\/10.1034\/j.1600-0773.2001.d01-118.x","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"4812_CR91","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0014-2999(00)00749-4","volume":"408","author":"KC Morley","year":"2000","unstructured":"Morley KC, McGregor IS (2000) (+\/\u2212)-3,4-methylenedioxymethamphetamine (MDMA, \u2018Ecstasy\u2019) increases social interaction in rats. Eur J Pharmacol 408(1):41\u201349. https:\/\/doi.org\/10.1016\/S0014-2999(00)00749-4","journal-title":"Eur J Pharmacol"},{"issue":"04","key":"4812_CR92","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1017\/S1461145712000582","volume":"16","author":"M Mueller","year":"2013","unstructured":"Mueller M, Yuan J, McCann UD, Hatzidimitriou G, Ga R (2013) Single oral doses of (\u00b1) 3,4-methylenedioxymethamphetamine (\u2018Ecstasy\u2019) produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations. Int J Neuropsychopharmacol 16(04):791\u2013801. https:\/\/doi.org\/10.1017\/S1461145712000582","journal-title":"Int J Neuropsychopharmacol"},{"key":"4812_CR93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neubiorev.2015.12.010","volume":"62","author":"F Mueller","year":"2016","unstructured":"Mueller F, Lenz C, Steiner M, Dolder PC, Walter M, Lang UE, Liechti ME, Borgwardt S (2016) Neuroimaging in moderate MDMA use: a systematic review. Neurosci Biobehav Rev 62:21\u201334. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.12.010","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"4812_CR94","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2165\/00003495-198325040-00004","volume":"25","author":"EE Muller","year":"1983","unstructured":"Muller EE, Locatelli V, Cella S, Penalva A, Novelli A, Cocchi D (1983) Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs 25(4):399\u2013432. https:\/\/doi.org\/10.2165\/00003495-198325040-00004","journal-title":"Drugs"},{"issue":"2","key":"4812_CR95","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.110.166595","volume":"334","author":"KS Murnane","year":"2010","unstructured":"Murnane KS, Fantegrossi WE, Godfrey JR, Banks ML, Howell LL (2010) Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys. J Pharmacol Exp Ther 334(2):642\u2013650. https:\/\/doi.org\/10.1124\/jpet.110.166595","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4812_CR96","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.yhbeh.2011.10.012","volume":"61","author":"KS Murnane","year":"2012","unstructured":"Murnane KS, Kimmel HL, Rice KC, Howell LL (2012) The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): a concurrent microdialysis and plasma analysis study. Horm Behav 61(2):181\u2013190. https:\/\/doi.org\/10.1016\/j.yhbeh.2011.10.012","journal-title":"Horm Behav"},{"issue":"1-2","key":"4812_CR97","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0304-3940(94)90057-4","volume":"177","author":"JF Nash","year":"1994","unstructured":"Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA (1994) Effect of the R(\u2212) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177(1-2):111\u2013115. https:\/\/doi.org\/10.1016\/0304-3940(94)90057-4","journal-title":"Neurosci Lett"},{"issue":"2","key":"4812_CR98","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0278-5846(98)00100-6","volume":"23","author":"JF Navarro","year":"1999","unstructured":"Navarro JF, Maldonado E (1999) Behavioral profile of 3,4-methylenedioxy-methamphetamine (MDMA) in agonistic encounters between male mice. Prog Neuro-Psychopharmacol Biol Psychiatry 23(2):327\u2013334. https:\/\/doi.org\/10.1016\/S0278-5846(98)00100-6","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"4","key":"4812_CR99","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18(4):305\u2013313. https:\/\/doi.org\/10.1080\/02791072.1986.10472362","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"4812_CR100","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/jm00347a010","volume":"25","author":"DE Nichols","year":"1982","unstructured":"Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GKW (1982) Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. J Med Chem 25(5):530\u2013535. https:\/\/doi.org\/10.1021\/jm00347a010","journal-title":"J Med Chem"},{"issue":"3","key":"4812_CR101","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0022-3565(25)22947-0","volume":"255","author":"R Oberlender","year":"1990","unstructured":"Oberlender R, Nichols DE (1990) (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. J Pharmacol Exp Ther 255(3):1098\u20131106","journal-title":"J Pharmacol Exp Ther"},{"key":"4812_CR102","first-page":"188","volume":"136","author":"JP O'Callaghan","year":"1993","unstructured":"O'Callaghan JP, Miller DB (1993) Quantification of reactive gliosis as an approach to neurotoxicity assessment. NIDA Res Monogr 136:188\u2013212","journal-title":"NIDA Res Monogr"},{"issue":"1","key":"4812_CR103","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (+\/\u2212 3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol (Oxf, Engl) 27(1):40\u201352. https:\/\/doi.org\/10.1177\/0269881112464827","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"issue":"4","key":"4812_CR104","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hup.2318","volume":"28","author":"AC Parrott","year":"2013","unstructured":"Parrott AC (2013) Human psychobiology of MDMA or \u2018Ecstasy\u2019: an overview of 25 years of empirical research. Hum Psychopharmacol 28(4):289\u2013307. https:\/\/doi.org\/10.1002\/hup.2318","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"4812_CR105","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/02791072.2014.873690","volume":"46","author":"AC Parrott","year":"2014","unstructured":"Parrott AC (2014) The potential dangers of using MDMA for psychotherapy. J Psychoactive Drugs 46(1):37\u201343. https:\/\/doi.org\/10.1080\/02791072.2014.873690","journal-title":"J Psychoactive Drugs"},{"issue":"8","key":"4812_CR106","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/FBP.0000000000000262","volume":"27","author":"AC Parrott","year":"2016","unstructured":"Parrott AC (2016) Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational \u2018ecstasy\u2019. Behav Pharmacol 27(8):649\u2013658. https:\/\/doi.org\/10.1097\/FBP.0000000000000262","journal-title":"Behav Pharmacol"},{"issue":"3","key":"4812_CR107","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2045125315583786","volume":"5","author":"R Patel","year":"2015","unstructured":"Patel R, Titheradge D (2015) MDMA for the treatment of mood disorder: all talk no substance? Ther adv Psychopharmacol 5(3):179\u2013188. https:\/\/doi.org\/10.1177\/2045125315583786","journal-title":"Ther adv Psychopharmacol"},{"issue":"1","key":"4812_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-8-376","volume":"8","author":"G-JY Peters","year":"2008","unstructured":"Peters G-JY, Kok G, Schaalma HP (2008) Careers in ecstasy use: do ecstasy users cease of their own accord? Implications for intervention development. BMC Public Health 8(1):376. https:\/\/doi.org\/10.1186\/1471-2458-8-376","journal-title":"BMC Public Health"},{"key":"4812_CR109","unstructured":"Philipps D (2016) F.D.A. agrees to new trials for ecstasy as relief for PTSD patients. New York Times"},{"issue":"3","key":"4812_CR110","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.janxdis.2010.11.010","volume":"25","author":"RH Pietrzak","year":"2011","unstructured":"Pietrzak RH, Goldstein RB, Southwick SM, Grant BF (2011) Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety disord 25(3):456\u2013465. https:\/\/doi.org\/10.1016\/j.janxdis.2010.11.010","journal-title":"J Anxiety disord"},{"issue":"10","key":"4812_CR111","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/npp.2017.80","volume":"42","author":"EG Pitts","year":"2017","unstructured":"Pitts EG, Minerva AR, Chandler EB, Kohn JN, Logun MT, Sulima A, Rice KC, Howell LL (2017) 3,4-Methylenedioxymethamphetamine increases affiliative behaviors in squirrel monkeys in a serotonin 2A receptor-dependent manner. Neuropsychopharmacology 42(10):1962\u20131971. https:\/\/doi.org\/10.1038\/npp.2017.80","journal-title":"Neuropsychopharmacology"},{"issue":"2-3","key":"4812_CR112","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.drugalcdep.2011.04.017","volume":"118","author":"R Procopio-Souza","year":"2011","unstructured":"Procopio-Souza R, Fukushiro DF, Trombin TF, Wuo-Silva R, Zanlorenci LH, Lima AJ, Ribeiro LT, Correa JM, Marinho EA, Kameda SR, Andersen ML, Tufik S, Frussa-Filho R (2011) Effects of group exposure on single injection-induced behavioral sensitization to drugs of abuse in mice. Drug Alcohol Depend 118(2-3):349\u2013359. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.04.017","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"4812_CR113","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/npp.2013.125","volume":"38","author":"L Ramos","year":"2013","unstructured":"Ramos L, Hicks C, Kevin R, Caminer A, Narlawar R, Kassiou M, McGregor IS (2013) Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology 38(11):2249\u20132259. https:\/\/doi.org\/10.1038\/npp.2013.125","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"4812_CR114","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/02791072.1994.10472600","volume":"26","author":"TJ Riedlinger","year":"1994","unstructured":"Riedlinger TJ, Riedlinger JE (1994) Psychedelic and entactogenic drugs in the treatment of depression. J Psychoactive Drugs 26(1):41\u201355. https:\/\/doi.org\/10.1080\/02791072.1994.10472600","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"4812_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13050","volume":"13","author":"G Rogers","year":"2009","unstructured":"Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, Zawada A, Somerville M (2009) The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 13(5):1\u2013315. https:\/\/doi.org\/10.3310\/hta13050","journal-title":"Health Technol Assess"},{"issue":"5","key":"4812_CR116","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2174\/1570159X11311050007","volume":"11","author":"P S\u00e1ez-Briones","year":"2013","unstructured":"S\u00e1ez-Briones P, Hern\u00e1ndez A (2013) MDMA (3,4-methylenedioxymethamphetamine) analogues as tools to characterize MDMA-like effects: an approach to understand entactogen pharmacology. Curr Neuropharmacol 11(5):521\u2013534. https:\/\/doi.org\/10.2174\/1570159X11311050007","journal-title":"Curr Neuropharmacol"},{"key":"4812_CR117","unstructured":"SAMHSA (Substance Abuse and Mental Health Services Administration) (2002) Office of Applied Studies. Mortality data from the drug abuse warning network, 2001. DAWN Series D-23, DHHS Publication No. (SMA) 03\u20133781. Rockville, MD"},{"issue":"11","key":"4812_CR118","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1111\/j.1460-9568.2007.05932.x","volume":"26","author":"S Schenk","year":"2007","unstructured":"Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC (2007) MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 26(11):3229\u20133236. https:\/\/doi.org\/10.1111\/j.1460-9568.2007.05932.x","journal-title":"Eur J Neurosci"},{"issue":"5","key":"4812_CR119","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/0006-2952(87)90729-5","volume":"36","author":"CJ Schmidt","year":"1987","unstructured":"Schmidt CJ, Levin JA, Lovenberg W (1987) In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36(5):747\u2013755. https:\/\/doi.org\/10.1016\/0006-2952(87)90729-5","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"4812_CR120","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1124\/mol.63.6.1223\\r63\/6\/1223 [pii]","volume":"63","author":"V Setola","year":"2003","unstructured":"Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63(6):1223\u20131229. https:\/\/doi.org\/10.1124\/mol.63.6.1223\\r63\/6\/1223 [pii]","journal-title":"Mol Pharmacol"},{"issue":"6","key":"4812_CR121","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.neuro.2008.07.005","volume":"29","author":"K Shioda","year":"2008","unstructured":"Shioda K, Nisijima K, Yoshino T, Kuboshima K, Iwamura T, Yui K, Kato S (2008) Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 29(6):1030\u20131036. https:\/\/doi.org\/10.1016\/j.neuro.2008.07.005","journal-title":"Neurotoxicology"},{"key":"4812_CR122","volume-title":"Pihkal: a chemical love story","author":"A Shulgin","year":"1991","unstructured":"Shulgin A, Shulgin A (1991) Pihkal: a chemical love story. Transform Press, Berkeley"},{"issue":"6","key":"4812_CR123","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.addbeh.2010.01.010","volume":"35","author":"RC Smith","year":"2010","unstructured":"Smith RC, Blumenthal H, Badour C, Feldner MT (2010) An investigation of relations between crystal methamphetamine use and posttraumatic stress disorder. Addict Behav 35(6):625\u2013627. https:\/\/doi.org\/10.1016\/j.addbeh.2010.01.010","journal-title":"Addict Behav"},{"issue":"8","key":"4812_CR124","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1360-0443.1992.tb02003.x","volume":"87","author":"N Solowij","year":"1992","unstructured":"Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of \u2018Ecstacy\u2019 users and their experiences with the drug. Br J Addict 87(8):1161\u20131172. https:\/\/doi.org\/10.1111\/j.1360-0443.1992.tb02003.x","journal-title":"Br J Addict"},{"issue":"2","key":"4812_CR125","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0028-3908(01)00060-0","volume":"41","author":"M Spitzer","year":"2001","unstructured":"Spitzer M, Franke B, Walter H, Buechler J, Wunderlich AP, Schwab M, Kovar KA, Hermle L, Gron G (2001) Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology 41(2):263\u2013271. https:\/\/doi.org\/10.1016\/S0028-3908(01)00060-0","journal-title":"Neuropharmacology"},{"issue":"3","key":"4812_CR126","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF02245967","volume":"118","author":"JE Sprague","year":"1995","unstructured":"Sprague JE, Nichols DE (1995) Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology 118(3):357\u2013359. https:\/\/doi.org\/10.1007\/BF02245967","journal-title":"Psychopharmacology"},{"issue":"3","key":"4812_CR127","first-page":"427","volume":"19","author":"JE Sprague","year":"1998","unstructured":"Sprague JE, Everman SL, Nichols DE (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19(3):427\u2013441","journal-title":"Neurotoxicology"},{"issue":"14","key":"4812_CR128","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/0006-2952(87)90594-6","volume":"36","author":"TD Steele","year":"1987","unstructured":"Steele TD, Nichols DE, Yim GKW (1987) Stereochemical effect S and related amphetamine derivatives on inhibition of uptake of [3H] monoamines synaptosomes from different regions into of rat brain. Biochem Pharmacol 36(14):2297\u20132303. https:\/\/doi.org\/10.1016\/0006-2952(87)90594-6","journal-title":"Biochem Pharmacol"},{"key":"4812_CR129","unstructured":"Stolaroff MJ (2004) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies (MAPS), Sarasota, FL"},{"issue":"1","key":"4812_CR130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-3565(25)20051-9","volume":"247","author":"DM Stone","year":"1988","unstructured":"Stone DM, Johnson M, Hanson GR, Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 247(1):79\u201387","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4812_CR131","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0376-8716(01)00146-6","volume":"65","author":"M Tancer","year":"2001","unstructured":"Tancer M, Johanson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65(1):97\u2013101. https:\/\/doi.org\/10.1016\/S0376-8716(01)00146-6","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"4812_CR132","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0376-8716(03)00172-8","volume":"72","author":"M Tancer","year":"2003","unstructured":"Tancer M, Johanson CE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72(1):33\u201344. https:\/\/doi.org\/10.1016\/S0376-8716(03)00172-8","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"4812_CR133","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00213-013-3288-1","volume":"231","author":"L Taurah","year":"2014","unstructured":"Taurah L, Chandler C, Sanders G (2014) Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Psychopharmacology 231(4):737\u2013751. https:\/\/doi.org\/10.1007\/s00213-013-3288-1","journal-title":"Psychopharmacology"},{"issue":"2","key":"4812_CR134","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neuroscience.2007.02.032","volume":"146","author":"MR Thompson","year":"2007","unstructured":"Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (\u201cecstasy\u201d). Neuroscience 146(2):509\u2013514. https:\/\/doi.org\/10.1016\/j.neuroscience.2007.02.032","journal-title":"Neuroscience"},{"issue":"4","key":"4812_CR135","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","volume":"189","author":"CD Verrico","year":"2007","unstructured":"Verrico CD, Miller GM, Madras BK (2007) MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189(4):489\u2013503. https:\/\/doi.org\/10.1007\/s00213-005-0174-5","journal-title":"Psychopharmacology"},{"issue":"5","key":"4812_CR136","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol (Oxf, Engl) 31(5):576\u2013588. https:\/\/doi.org\/10.1177\/0269881117691569","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"issue":"3","key":"4812_CR137","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","volume":"27","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Schmid Y, Prestin K, Meyer Z, Schwabedissen HE, Liechti ME (2017) Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 27(3):232\u2013238. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.01.008","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"issue":"4","key":"4812_CR138","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0893-133X(98)00013-X","volume":"19","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (\u2018Ecstasy\u2019) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19(4):241\u2013251. https:\/\/doi.org\/10.1016\/S0893-133X(98)00013-X","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"4812_CR139","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00213-006-0599-5","volume":"189","author":"Z Wang","year":"2007","unstructured":"Wang Z, Woolverton WL (2007) Estimating the relative reinforcing strength of (+\/\u2212)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology 189(4):483\u2013488. https:\/\/doi.org\/10.1007\/s00213-006-0599-5","journal-title":"Psychopharmacology"},{"issue":"1","key":"4812_CR140","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10567-009-0062-3","volume":"13","author":"SW White","year":"2010","unstructured":"White SW, Albano AM, Johnson CR, Kasari C, Ollendick T, Klin A, Oswald D, Scahill L (2010) Development of a cognitive-behavioral intervention program to treat anxiety and social deficits in teens with high-functioning autism. Clin Child Fam Psychol Rev 13(1):77\u201390. https:\/\/doi.org\/10.1007\/s10567-009-0062-3","journal-title":"Clin Child Fam Psychol Rev"},{"issue":"12","key":"4812_CR141","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/sj.npp.1301031","volume":"31","author":"T Xie","year":"2006","unstructured":"Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, Ricaurte G (2006) Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31(12):2639\u20132651. https:\/\/doi.org\/10.1038\/sj.npp.1301031","journal-title":"Neuropsychopharmacology"},{"key":"4812_CR142","doi-asserted-by":"crossref","unstructured":"Young R, Glennon R (2008) MDMA (N-methyl-3,4-methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice. Pharmacol Biochem Behav 88(3):318\u2013331","DOI":"10.1016\/j.pbb.2007.09.002"},{"issue":"9","key":"4812_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.138","volume":"5","author":"MB Young","year":"2015","unstructured":"Young MB, Andero R, Ressler KJ, Howell LL (2015) 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry 5(9):e634. https:\/\/doi.org\/10.1038\/tp.2015.138","journal-title":"Transl Psychiatry"},{"issue":"19","key":"4812_CR144","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s00213-017-4684-8","volume":"234","author":"MB Young","year":"2017","unstructured":"Young MB, Norrholm SD, Khoury LM, Jovanovic T, Rauch SAM, Reiff CM, Dunlop BW, Rothbaum BO, Howell LL (2017) Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology 234(19):2883\u20132895. https:\/\/doi.org\/10.1007\/s00213-017-4684-8","journal-title":"Psychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4812-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T22:19:02Z","timestamp":1751149142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4812-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,16]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4812"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4812-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,16]]},"assertion":[{"value":"19 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.B.Y. became employed by Shire Pharmaceuticals (Lexington, MA, USA) after completion of the studies described herein. M.B.Y. was supported by a NIH\/NIGMS IRACDA grant K21 GM000680 awarded to Emory University. L.L.H. was supported by NIH\/NIDA K05 DA031246. The Yerkes National Primate Research Center is supported by NIH P51OD11132. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}